Loading...
Loading...
TARA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 12.1M |
| Operating I/L | -12.1M |
| Other Income/Expense | 0.8M |
| Interest Income | 0.8M |
| Pretax | -11.3M |
| Income Tax Expense | -0.8M |
| Net Income/Loss | -11.3M |
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing transformative therapies for cancer and rare diseases. Its lead program, TARA-002, is an investigational cell therapy for lymphatic malformations, and it also focuses on intravenous choline chloride for intestinal failure associated liver disease. The company generates revenue through the development and potential commercialization of these innovative therapies, aiming to address unmet medical needs in the market.
